As SNIPR BIOME's Phase 1 trial ends, Eric van der Helm discusses SNIPR001, a precision platform that uses #CRISPR-armed #phages to prevent life-threatening bloodstream #infections in #cancer patients without disrupting their #microbiomes. #AMR Story @carb_x bit.ly/41ssNAA

Earlier this month we published the science leading up to SNIPR001 in Nature Biotechnology. We were invited to also provide a ‘behind-the-scenes’ of how this project came together, you can now read the blog post here👇

🎉In an incredible milestone for our team and science as a whole, I'm proud to announce the promising results of our pioneering CRISPR-based microbial gene phage therapy, SNIPR001.

A great example from the Baker lab on how de novo protein design can be very powerful if you have the right problem. In this case, achieving very high selectivity for a receptor subtype and trapping it in a very specific conformation. biorxiv.org/content/10.110… Short 🧵

A study in Nature Communications explores the distribution, evolution and functions of the K1 capsule at a population level and its important role in the pathogenesis of E. coli. go.nature.com/42SBl3Q

A recent study by SNIPR Biome confirmed the feasibility of using CRISPR-armed phages to selectively target clinically-relevant E. coli. The findings highlight new possibilities in using phage therapy to treat antibiotic-resistant bacteria. Read more: shorturl.at/depDU

Exciting news: SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into Phase 1b/2a clinical trials in haematological cancer patients! 👇globenewswire.com/news-release/2…

One of the many perks as an Unveil Bio customer: Edible plasmids! Get your plasmids sequenced at eu1.hubs.ly/H09t7x-0

We are pleased to share that SNIPR Biome has received funding from the Gates Foundation to advance our microbial gene therapy platform aimed at improving Environmental Enteric Dysfunction in pregnant women from low- and middle-income countries (LMICs). static1.squarespace.com/static/5bacc67…

Great to see David Baker’s groundbreaking work recognized with the 2024 Nobel Prize in Chemistry. It was an incredible experience to have worked in his lab at the Institute for Protein Design over a decade ago and to see the work he's been honored for today!

Want to know more about building large #phage libraries using cell-free synthesis? Check out our new SNIPR BIOME scientific article in Synthetic Biology. Big congrats to PhD student Camilla Schoopp Kristensen for leading this work.

Seven days to #BioEurope! Reach out if you are at #BioEurope and want to know more about SNIPR BIOME progress in AMR and Microbial Gene Therapy.

Attending #JPM2025 this January? christian groendahl and Eric van der Helm will be present and involved in JPM week events. Reach out if you want to meet in San Francisco!

On February 25-26, christian groendahl and I will be in Basel for the #AMRConference. We’re excited to discuss how SNIPR BIOME CRISPR technology can help combat #AntimicrobialResistance. If you're attending, feel free to reach out via [email protected]

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis

SNIPR Biome strengthens IP portfolio with a patent granted for a novel #CRISPR-Cas system! Read more in the press release below.

I’m looking forward to meeting everyone in Berlin next week, so if you’re also attending SPRIND, Federal Agency for Breakthrough Innovation feel free to send me a message

christian groendahl and Eric van der Helm will be attending next week's #BioEquity in Bruges🇧🇪. Reach out to learn more about our recent progress and updates of our pipeline. #partnering #BioEquityEurope

Looking forward to meeting at #BIO2025! Reach out if you'd like to connect with christian groendahl and Eric van der Helm in Boston June 16-19. DM here or email [email protected]

Very proud to see our lead asset now being dosed in patients for the first time. Big congrats to the whole team!